How much revenue does Bioasis Technologies make?

Bioasis Technologies reported 37,725 CAD in revenue for fiscal year 2022, down 99.1% from 4.08 million CAD in fiscal year 2021. In Q3 2023 revenue was 148,936 CAD.

What companies are similar to Bioasis Technologies?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include RenovaCare, Inc. (RCAR), Alliance Growers Corp. (ALGWF), Gsrx Industries Inc. (GSRX), Winston Pharmaceuticals, Inc. (WPHM).

Bioasis Technologies Inc. (BIOAF) Stock

About Bioasis Technologies Inc.

Bioasis Technologies Inc. operates as a biopharmaceutical company. The company utilizes its proprietary xB3 platform to deliver therapeutics across the blood-brain barrier and treat central nervous system disorders in areas of high unmet medical need. Bioasis Technologies Inc. is based in New Haven, Connecticut.

At a glance

Bioasis Technologies reported revenue of 37,725 CAD for fiscal year 2022, down 99.1% from fiscal year 2021, and net income of -2.96 million CAD. In Q3 2023 (the quarter ended November 30, 2022) revenue was 148,936 CAD, up 294.8% from a year before.

Figures from company filings; latest fiscal year ended February 28, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.